DSpace logo

Please use this identifier to cite or link to this item: http://142.54.178.187:9060/xmlui/handle/123456789/13587
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHafeez, Freeha-
dc.contributor.authorZahoor, Ameer Fawad-
dc.contributor.authorRasul, Azhar-
dc.contributor.authorAhmad, Sajjad-
dc.contributor.authorMansha, Asim-
dc.date.accessioned2022-10-24T08:47:50Z-
dc.date.available2022-10-24T08:47:50Z-
dc.date.issued2021-01-16-
dc.identifier.issn1011-601X-
dc.identifier.urihttp://142.54.178.187:9060/xmlui/handle/123456789/13587-
dc.description.abstractPiperazine moiety is found as an efficient pharmacological scaffold in various drugs. To explore the anticancer potential of piperazine framework, a series of novel N-acetamides derivatives of phenyl piperazine containing di-thio-carbamate moiety was designed and synthesized. 1HNMR, 13CNMR, FT-IR and mass spectrometry were used for the structures elucidation of these derivatives. In-vitro cytotoxic evaluation of the prepared novel compounds against lung carcinoma A-549 was carried out using standard MTT assay. All the di-thio-carbamate-piperazine derivatives exhibited moderate to excellent cytotoxic potential against A-549 cell line based on cell viability. Particularly, 6e was found to be the most potent derivative with cell viability 34.12±0.73 % at 100 µg/mL concentration and represents promising lead compound for future progress.en_US
dc.language.isoenen_US
dc.publisherKarachi: Faculty of Pharmacy & Pharmaceutical Sciecnes, University of Karachien_US
dc.subjectN-Phenyl piperazineen_US
dc.subjectcytotoxicityen_US
dc.subjectdi-thio-carbamatesen_US
dc.subjecthuman lung canceren_US
dc.subjectanti-canceren_US
dc.titleSynthesis and anticancer evaluation of 2-oxo-2-(arylamino) ethyl 4- phenylpiperazine-1-carbodithioatesen_US
dc.typeArticleen_US
Appears in Collections:Issue 01 (Supplementary)

Files in This Item:
File Description SizeFormat 
19-SUP-1664.htm148 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.